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Abstract Öz 
Purpose: The aim of this study was to evaluate the 
relationship between leptin and weight gain in patients 
receiving iron treatment. 
Materials and Methods: A total of 42 female patients 
who were diagnosed with IDA were included in the study. 
Whole blood count, serum iron, serum unsaturated iron 
binding capacity (UIBC), serum ferritin level were 
measured at the time of diagnosis and on month one after 
treatment; serum hepcidin level and serum leptin level 
were measured at the time of diagnosis and 96 hours after 
commencement of parenteral therapy; body weight and 
appetite alterations were recorded at the time of diagnosis 
and on month one. 
Results: A statistically significant difference was not 
found between hepcidin and leptin values at the time of 
diagnosis and after treatment. Increased appetite was 
detected in 22 (52.4%) patients on month one after 
treatment. While mean weight of all patients was 
69.6±17.9 kg at the time of diagnosis, it was 70.7±17.5 kg 
on month one after treatment and there was a statistically 
significant difference between two values.  
Conclusion: Our study revealed that appetite and body 
weight increased following iron therapy, consistently with 
our observations and hypothesis. However no significant 
relationship was found with leptin levels and weight 
increase.  
Amaç: Bu çalışmanın amacı demir tedavisi alan hastalarda 
leptin ve kilo artışı arasındaki ilişkiyi saptamaktır. 
Gereç ve Yöntem: Toplamda 42 demir eksikliği anemisi 
tanısı konulan kadın hasta çalışmaya dahil edilmiştir. Tanı 
anında ve tedavi başlandıktan 1 ay sonra tam kan sayımı, 
serum demir, ansature demir bağlama kapasitesi ve ferritin 
seviyesi, tanı anında ve tedavi başlandıktan sonra 96. saatte 
serum hepsidin ve leptin seviyesi ölçüldü. İştahta meydana 
gelen değişiklikler ve vücut ağırlığı tanı anında ve tedavi 
başlandıktan 1 ay sonra değerlendirildi. 
Bulgular: Tanı anındaki ve tedavi başlandıktan sonraki 
serum hepsidin ve leptin seviyeleri arasında istatistiksel 
olarak anlamlı fark bulunmadı. 22 (%52.4) hastada iştah 
artışı olduğu tespit edildi.  Tanı anında hastaların ortalama 
ağırlığı 69.6±17.9 kg olarak tespit edilmiş iken tedavi 
başlandıktan 1 ay sonra hastaların ağırlığı 70.7±17.5 kg 
olarak bulunmuştur ve değerler arasında istatistiksel olarak 
anlamlı fark tespit edilmiştir. 
Sonuç: Çalışmamız gözlemlerimiz ve hipotezimizle 
uyumlu olarak demir tedavisini takiben hastalarda iştah 
artışı ve ağırlık artışı meydana geldiği saptanmıştır. Leptin 
düzeyleri ile kilo artışı arasında bir ilişki bulunmamıştır.  
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INTRODUCTION 
Anemia is an important health problem in all age 
groups1. Iron deficiency anemia (IDA) is the most 
common type of anemia2, and responsible for 
approximately 50% of anemias across worldwide3. 
IDA is present in more than 1.5 billion individual 
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worldwide4. According to the estimations of World 
Health Organization (WHO), 42% of pregnant 
women, 30% of non-pregnant women between ages 
15-50, 47% of pre-school children (0-5 years) and 
12.7% of male above 15 years are anemic3.  
Iron has been used for treatment of anemia for 
longer than 300 years5. Oral iron therapy is an 
effective, safe and inexpensive method6,7. However 
parenteral iron treatment is required instead of oral 
iron therapy under some conditions. Both treatment 
methods have some well-known side effects. 
Gastrointestinal side effects like nausea, heartburn, 
abdominal pain, diarrhea, constipation, metallic taste 
are the well-known side effects of oral iron 
therapy6,7. Late side effects mimicking serum disease 
like hypotension, urticaria, nausea, fatigue, 
musculoskeletal pain, lymphadenomegaly and 
anaphylaxis are the well-known side effects of 
parenteral iron therapy6,7. Despite the presence of 
anxiety and observations about body weight increase 
in clinical practice, sufficient data are not available 
about this issue. The main role of leptin which is 
synthesized mainly in adipose tissue is to regulate 
food intake and energy metabolism through the 
suppressive effect on brain (particularly 
hypothalamus) and to prevent obesity, namely it 
works as a satiety factor8,9. Hepcidin is a peptide 
hormone which regulates iron balance10. Hepcidin 
synthesis is stimulated by the increase of plasma iron 
levels and tissue iron deposits and it reduces iron 
release to plasma from macrophages and duodenal 
enterocytes11,12. Erythropoietic stimulants reduce 
hepcidin production in case of anemia or hypoxia, 
eliminate the inhibitor effect hepcidin on iron 
absorption and iron release from macrophages, 
enable more iron to be used for erythropoiesis11,12. 
In some recent studies, a relationship has been 
shown between the hormones affecting on appetite 
center and hepcidin13,14. Therefore, we planned this 
study under the light of these data considering that 
leptin levels may decrease together with the increase 
in hepcidin levels following iron therapy, potential 
appetite increase and body weight increase may be 
explained with this mechanism. 
MATERIALS AND METHODS 
This study was approved by Cumhuriyet University 
Ethics Committee (Project no: 2014-02/08; Date: 
02/17/2014). All procedures performed in studies 
involving human participants were in accordance 
with the ethical standards of the institutional and/or 
national research committee and with the 1964 
Helsinki declaration and its later amendments or 
comparable ethical standards. Informed consent was 
obtained from all individual participants included in 
the study. 
Study population 
This is a prospective, multi-center study. Patient 
selection is clinical-based and independent from 
etiology. A total of 42 female patients who were 
diagnosed with IDA according to WHO diagnostic 
criteria (hemoglobin <12 g/dL, serum ferritin level 
<15 ng/mL, and/or transferrin saturation <16%), 
administered parenteral iron therapy were included 
in the study. The patients who had severe 
endocrinologic, psychiatric, oncologic diseases, 
vitamin B12 or folate deficiency beside iron 
deficiency, using any medications which could 
influence appetite center and/or body weight were 
excluded from the study. 
Laboratory and clinical evaluation 
Whole blood count, serum iron, serum unsaturated 
iron binding capacity (UIBC), serum ferritin level 
were measured at the time of diagnosis and on 
month one after treatment; serum hepcidin level and 
serum leptin level were measured at the time of 
diagnosis and 96 hours after commencement of 
parenteral therapy; body weight and appetite 
alterations were recorded at the time of diagnosis 
and on month one.  
Serum iron, serum unsaturated iron binding capacity 
(UIBC) were studied using ferrozin method (Roche 
Diagnostics GmbH, Mannheim, Germany),serum 
ferritin level was studied using immunoturbidimetric 
method (Roche) and Cobas e 601 immunoassay 
analyzer (Roche). Transferrin saturation index was 
calculated using the formula: serum iron/total iron 
binding capacity (UIBC) x 100. Serum hepcidin level 
(Hangzhou Eastbiopharm Co., Ltd., China) and 
leptin level (eBioscience, Bender MedSystems 
GmbH, Vienna, Austria) were measured using 
ELISA kit before treatment and at 96th hour. Whole 
blood count of all patients was studied using Coulter 
LH 750 hematology analyzer (Beckman-Coulter, 
Brea, CA, USA). 
Treatment protocol 
The patients were treated with 2700-5400 mg iron 
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(Fe3+) hydroxyl sucrose complex equal to 100-200 
mg elemental iron by intravenous infusion at every 
other day according to the needs of the patients (a 
total of 3-5 doses). 
Statistical analysis 
Patient characteristics were evaluated using   
descriptive statistics. Continuous variables were 
given as mean ± standard deviation; categorical 
variables were given as percent. Chi-square and 
student’s t-test were used for comparison of percent 
and mean values. A p level of <0.05 was accepted as 
statistically significant. SPSS (SPSS 17.0 for 
Windows, Inc., Chicago, IL, USA) program was 
used for all statistical calculations. 
RESULTS 
Mean age was found as 36.2 ± 9.2 years. Data of the 
patients about whole blood count and iron 
parameters before treatment and at month one after 
treatment are given in Table 1.  
Table 1. Pre-treatment and post-treatment data of the patients 
Parameter  Pre-treatment Post-treatment (1st month) 
Leukocyte  (×103 /µL) 6.7±1.7 6.3±1.2 
Erythrocyte (×1012 /L) 4.42±0.46 4.90±0.36 
Hemoglobin (g/dL) 8.4±1.3 11.5±1.0 
Hematocrit (%) 27.7±3.6 36.0±2.7 
MCV (fL) 62.7±5.7 73.6±4.7 
Platelet  (x109 /L) 355±128 311±90 
Iron  (µg/dL) 19.9±5.7 58.1±22.2 
UIBC (µg/dL) 443.5±52.0 329.9±54.3 
Ferritin (ng/mL) 4.6±2.6 56±33.3 
MCV: mean corpuscular volume; UIBC: unsaturated iron binding capacity 
 
Hepcidin and leptin values before treatment and 96 
hours after treatment are given in Table 2. A 
statistically significant difference was not found 
between hepcidin and leptin values at the time of 
diagnosis and after treatment. A correlation was 
detected between hepcidin and leptin values 
considering the variation between levels at the time 
of diagnosis and after treatment (r=-0.27, p=0.867). 
Increased appetite was detected in 22 (52.4%) 
patients on month one after treatment. While mean 
weight of all patients was 69.6±17.9 kg at the time 
of diagnosis, it was 70.7±17.5 kg on month one 
after treatment and there was a statistically 
significant difference between two values (p<0.001). 
In addition, a poor correlation was detected between 
weight increase and variation in hepcidin values 
(r=0.123, p=0.439), between weight increase and 
variation in leptin values (r=-0.064, p=0.685). 
Table 2. Hepcidin and leptin values before treatment and 96 hours after treatment 
Parameter  Before treatment After treatment P value 
Serum Hepcidin (g/L) 51.2±42.7 64.5±53.1 0.092 
Serum Leptin (pg/mL) 368.2±278.5 333.2±233.8 0.258 
 
DISCUSSION 
Individuals with iron deficiency have appetite loss, 
while dietary iron supplementation is associated with 
increased appetite in children15. The mechanism 
underlying these associations is poorly understood15. 
Therefore, we investigated the effect of iron on 
appetite and body weight associated with leptin. 
Results of our study revealed the influences of iron 
therapy on appetite and body weight increase. 
Serum hepcidin level was observed to increase and 
serum leptin level was observed to decrease after 
commencement of iron therapy, although results 
were not statistically significant. Similarly to our 
study, Doğan et al.13 detected an increase in serum 
hepcidin level and a decrease in serum leptin levels, 
although statistically insignificant in their study 
conducted with 30 children with IDA. Serum 
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ghrelin level was also examined in their study and it 
was detected to increase13. There are some 
differences between this study and our study; the 
patient populations composed of children, oral iron 
therapy was preferred, and level of ghrelin which is 
the contra-regulatory hormone of leptin and known 
as fasting hormone was examined. Detection of a 
reduction in serum leptin level and an increase in 
serum ghrelin level supports the close relationship 
between iron therapy and appetite-regulating 
hormones. 
Aukett et al.16 designed to determine the effect of 
psychomotor development of giving oral treatment. 
In this study toddlers with anemia who received 
treatment with iron for two months when compared 
with a control group with anemia who did not 
receive treatment with iron were different in two 
respects16. Aukett et al.16 detected a weight increase 
more than expected in iron therapy-receiving group 
compared to control group however they did not 
make an investigation about the mechanism of 
effect. Differently from our study, serum hormone 
levels were not examined in that study and the study 
conducted in children.   
In a current study, Gao et al.15 determined that 
dietary iron overload increases adipocyte iron and 
decreases mRNA and serum protein levels, and 
consequently iron-induced downregulation of leptin 
is associated with increased food intake in mice. 
They also found that human ferritin levels are 
inversely associated with serum leptin independently 
of inflammation and BMI15. Gao et al. have shown a 
reverse relationship between iron intake and leptin 
in their animal study, supporting our hypothesis. 
The human part of that study has focused on only 
the relationship between serum ferritin and leptin 
levels, but the influence of iron treatment on 
appetite and weight gain was not investigated, 
differently from our study. The major limitations of 
this study was small patient population of our study 
and potential difficulties for serum leptin level 
measurement (short half-life, diurnal and pulsatile 
secretion). 
In conclusion, sufficient and clear data are not 
available about this issue and we think that this 
effect of iron treatment is overlooked. Our study 
revealed that appetite and body weight increased 
following iron therapy, consistently with our 
observations and hypothesis. We consider that 
revealing the influence of iron therapy on appetite 
and body weight through larger and well designated 
studies would provide more data. 
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